• Home
• About Us
  • Overview
  • Management
  • Board of Directors
  • Dynavax Europe
  • Careers
• Pipeline
  • Overview
  • Hepatitis B Vaccine
  • Hepatitis C
  • Hepatitis B
  • Asthma
  • Autoimmunity / Inflammation
  • Flu Vaccine
• Partners
• Technology
  • Immune System
  • ISS
  • IRS
  • Publications
• Investors
  • Overview
  • News & Events
  • Stock Information
  • Analyst Coverage
  • Financials
  • SEC Filings
  • Corporate Governance
  • Contact Us
• Contact Us

About Us

Overview
Management
Board of Directors
Dynavax Europe
Careers

About Us :: Overview

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company committed to discovering and developing novel products to prevent and treat infectious diseases.  Our clinical-stage product candidates include:

• Phase 3 HEPLISAV ™ Hepatitis B Vaccine
• Phase 1 Hepatitis C Therapy
• Phase 1 Hepatitis B Therapy

In addition, we are developing a preclinical Universal Flu vaccine  and programs partnered with pharmaceutical companies, including AstraZeneca and GlaxoSmithKline.

Our European subsidiary Rhein Biotech manufactures hepatitis B surface antigen for HEPLISAV.  With 20 years in business, Rhein Biotech also provides integrated product development services to enable its partners to bring products to market.